$MGNX
MACROGENICS INC Stock $mgnx

$mgnx Overview Financials Valuation SEC Filings Company Website

2014 Q4 Form 10-Q Financial Statement

#000119312514407501 Filed on November 12, 2014

Income Statement

Concept	2014 Q4	2014 Q3	2013 Q3
Revenue	$5.476M	$18.38M	$20.23M
YoY Change	-63.26%	-9.14%	25.81%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.800M	$3.700M	$2.000M
YoY Change	26.32%	85.0%	33.33%
% of Gross Profit
Research & Development	$19.70M	$18.63M	$11.09M
YoY Change	37.76%	68.04%	-7.35%
% of Gross Profit
Depreciation & Amortization	$500.0K	$480.0K	$316.9K
YoY Change	38.89%	51.49%	34.52%
% of Gross Profit
Operating Expenses	$24.50M	$18.63M	$11.09M
YoY Change	35.36%	68.04%	-7.35%
Operating Profit		-$3.928M	$7.158M
YoY Change		-154.88%	175.42%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$0.00	$0.00	-$554.0K
YoY Change		-100.0%	-35681.25%
Pretax Income	-$19.00M	-$3.900M	$6.600M
YoY Change	493.75%	-159.09%	153.85%
Income Tax			$0.00
% Of Pretax Income			0.0%
Net Earnings	-$19.02M	-$3.928M	$6.604M
YoY Change	493.39%	-159.48%	153.9%
Net Earnings / Revenue	-347.3%	-21.37%	32.64%
Basic Earnings Per Share		-$0.14	$0.14
Diluted Earnings Per Share	-$681.0K	-$0.14	$0.01
COMMON SHARES
Basic Shares Outstanding	27.79M shares	27.75M shares	1.185M shares
Diluted Shares Outstanding		27.75M shares	21.24M shares

Balance Sheet

Concept	2014 Q4	2014 Q3	2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$157.6M	$179.2M	$33.60M
YoY Change	35.28%	433.33%
Cash & Equivalents	$157.6M	$179.2M	$33.57M
Short-Term Investments
Other Short-Term Assets	$4.200M	$2.500M	$1.100M
YoY Change	320.0%	127.27%
Inventory
Prepaid Expenses	$4.211M	$2.453M	$1.103M
Receivables	$2.935M	$5.315M	$2.281M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$164.7M	$187.0M	$36.95M
YoY Change	37.9%	405.92%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.785M	$5.633M	$4.470M
YoY Change	34.76%	26.02%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.064M	$733.0K	$147.2K
YoY Change	133.22%	397.81%
Total Long-Term Assets	$9.149M	$6.666M	$5.022M
YoY Change	44.65%	32.74%
TOTAL ASSETS
Total Short-Term Assets	$164.7M	$187.0M	$36.95M
Total Long-Term Assets	$9.149M	$6.666M	$5.022M
Total Assets	$173.9M	$193.6M	$41.98M
YoY Change	38.24%	361.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.669M	$4.388M	$1.798M
YoY Change	-47.33%	144.02%
Accrued Expenses	$7.930M	$4.031M	$939.8K
YoY Change	121.26%	328.92%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.600M	$1.600M	$1.200M
YoY Change	14.29%	33.33%
Total Short-Term Liabilities	$27.09M	$25.99M	$25.27M
YoY Change	-6.0%	2.86%
LONG-TERM LIABILITIES
Long-Term Debt	$6.400M	$6.800M	$8.400M
YoY Change	-20.0%	-19.05%
Other Long-Term Liabilities	$19.10M	$21.80M	$12.40M
YoY Change	91.0%	75.81%
Total Long-Term Liabilities	$25.50M	$28.60M	$20.80M
YoY Change	41.67%	37.5%
TOTAL LIABILITIES
Total Short-Term Liabilities	$27.09M	$25.99M	$25.27M
Total Long-Term Liabilities	$25.50M	$28.60M	$20.80M
Total Liabilities	$52.60M	$54.54M	$46.02M
YoY Change	12.23%	18.5%
SHAREHOLDERS EQUITY
Retained Earnings	-$214.0M	-$195.0M	-$172.5M
YoY Change	21.8%	13.04%
Common Stock	$280.0K	$278.0K	$21.25K
YoY Change	11.11%	1208.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$19.00K		$57.74K
YoY Change	-67.24%
Treasury Stock Shares
Shareholders Equity	$121.3M	$139.1M	-$4.048M
YoY Change
Total Liabilities & Shareholders Equity	$173.9M	$193.6M	$41.98M
YoY Change	38.24%	361.28%

Cashflow Statement

Concept	2014 Q4	2014 Q3	2013 Q3
OPERATING ACTIVITIES
Net Income	-$19.02M	-$3.928M	$6.604M
YoY Change	493.39%	-159.48%	153.9%
Depreciation, Depletion And Amortization	$500.0K	$480.0K	$316.9K
YoY Change	38.89%	51.49%	34.52%
Cash From Operating Activities	-$20.16M	-$14.34M	$810.0K
YoY Change	1608.47%	-1870.37%	-112.82%
INVESTING ACTIVITIES
Capital Expenditures	-$1.660M	-$670.0K	-$1.160M
YoY Change	80.43%	-42.24%	314.29%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$1.660M	-$670.0K	-$1.160M
YoY Change	80.43%	-42.24%	314.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	220.0K	180.0K	140.0K
YoY Change	-99.74%	28.57%	1300.0%
NET CHANGE
Cash From Operating Activities	-20.16M	-14.34M	810.0K
Cash From Investing Activities	-1.660M	-670.0K	-1.160M
Cash From Financing Activities	220.0K	180.0K	140.0K
Net Change In Cash	-21.60M	-14.83M	-210.0K
YoY Change	-126.05%	6961.9%	-96.81%
FREE CASH FLOW
Cash From Operating Activities	-$20.16M	-$14.34M	$810.0K
Capital Expenditures	-$1.660M	-$670.0K	-$1.160M
Free Cash Flow	-$18.50M	-$13.67M	$1.970M
YoY Change	7015.38%	-793.91%	-132.62%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	16955790	shares
CY2014Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	27794963	shares
CY2008Q3	mgnx	Onetime Milestone Payment To Be Paid Under Agreement OnetimeMilestonePaymentToBePaidUnderAgreement	5000000
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33569000
CY2014Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27772085	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2955117	shares
CY2014Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.62
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1756293	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.45
CY2014Q3	us-gaap	Treasury Stock Number Of Shares Held TreasuryStockNumberOfSharesHeld	0	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	6.35
CY2014Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3128950	shares
CY2014Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	363000
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	916000
CY2014Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	19052000
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	507000
CY2014Q3	us-gaap	Liabilities Current LiabilitiesCurrent	25988000
CY2014Q3	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	1589000
CY2014Q3	us-gaap	Common Stock Value CommonStockValue	278000
CY2014Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	4388000
CY2014Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-195028000
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	4291000
CY2014Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4031000
CY2014Q3	us-gaap	Stockholders Equity StockholdersEquity	139088000
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	17060000
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	3348000
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	4166000
CY2014Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	193625000
CY2014Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	333838000
CY2014Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	15617000
CY2014Q3	us-gaap	Restructuring Reserve Noncurrent RestructuringReserveNoncurrent	6789000
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	3832000
CY2014Q3	us-gaap	Liabilities Liabilities	54537000
CY2014Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	2708000
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	179191000
CY2014Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5633000
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	46144000
CY2014Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	179491000
CY2014Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	300000
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	44305000
CY2014Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	32646000
CY2014Q3	us-gaap	Assets Assets	193625000
CY2014Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	153145000
CY2014Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	9100000
CY2014Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5315000
CY2014Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	733000
CY2014Q3	us-gaap	Assets Current AssetsCurrent	186959000
CY2014Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2453000
CY2014Q3	mgnx	Money Market Funds Fair Value Disclosure MoneyMarketFundsFairValueDisclosure	26046000
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47743000
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25177597	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.90
CY2013Q4	us-gaap	Treasury Stock Number Of Shares Held TreasuryStockNumberOfSharesHeld	14381	shares
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3200958	shares
CY2013Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	363000
CY2013Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	7136000
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	28822000
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	125782000
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	254453000
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	20267000
CY2013Q4	us-gaap	Restructuring Reserve Noncurrent RestructuringReserveNoncurrent	8006000
CY2013Q4	us-gaap	Liabilities Liabilities	46868000
CY2013Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	2904000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	116481000
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5035000
CY2013Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	116886000
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	405000
CY2013Q4	us-gaap	Assets Assets	125782000
CY2013Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	90434000
CY2013Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	1439000
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	252000
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3169000
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-175733000
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3584000
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	78914000
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2004000
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	885000
CY2013Q4	us-gaap	Treasury Stock Value TreasuryStockValue	58000
CY2013Q4	us-gaap	Assets Current AssetsCurrent	119457000
CY2013Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	972000
CY2013Q4	mgnx	Money Market Funds Fair Value Disclosure MoneyMarketFundsFairValueDisclosure	26047000
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	20445061	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Discount For Postvesting Restrictions ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions	0.0506	pure
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-12988000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P7Y
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21908859	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1463798	shares
	us-gaap	Revenue From Grants RevenueFromGrants	1112000
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	42016000
	us-gaap	Operating Income Loss OperatingIncomeLoss	3571000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-627000
	us-gaap	Revenues Revenues	43128000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2037000
	us-gaap	Net Income Loss NetIncomeLoss	2944000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	235000
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	966000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-13969000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32234000
	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	-466000
	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Basic ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic	2944000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-14174000
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	626000
	us-gaap	Depreciation Depreciation	835000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	851000
	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	2944000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-297000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-2037000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	851000
	us-gaap	Costs And Expenses CostsAndExpenses	39557000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7323000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1941000
	us-gaap	Share Based Compensation ShareBasedCompensation	394000
	mgnx	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	87000
	mgnx	Contingent Consideration Recorded As Incremental In Process Research And Development Expense ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense	0
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.71
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	279894	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y6M
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.41
	dei	Document Type DocumentType	10-Q
	dei	Entity Registrant Name EntityRegistrantName	MACROGENICS INC
	dei	Trading Symbol TradingSymbol	MGNX
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	14.75
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Discount For Postvesting Restrictions ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions	0.0500	pure
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P4Y
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-12595000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	44698	shares
	dei	Document Period End Date DocumentPeriodEndDate	2014-09-30
	us-gaap	Lessee Leasing Arrangements Operating Leases Renewal Term LesseeLeasingArrangementsOperatingLeasesRenewalTerm	P5Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M12D
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.42
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27227151	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.71
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	20.72
	dei	Entity Central Index Key EntityCentralIndexKey	0001125345
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.67	pure
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	307204	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27227151	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	2000000
	us-gaap	Revenue From Grants RevenueFromGrants	435000
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-19295000
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	41886000
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-152000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-19296000
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	-105000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1000
	us-gaap	Revenues Revenues	42321000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1914000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19295000
	us-gaap	Net Income Loss NetIncomeLoss	-19295000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3311000
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1481000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	7266000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	50536000
	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	-1067000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	62710000
	us-gaap	Depreciation Depreciation	1317000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	77219000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	76733000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	447000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1914000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	486000
	us-gaap	Costs And Expenses CostsAndExpenses	61617000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11081000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1219000
	us-gaap	Share Based Compensation ShareBasedCompensation	2249000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	8200000
	mgnx	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	-196000
	mgnx	Contingent Consideration Recorded As Incremental In Process Research And Development Expense ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense	0
	mgnx	Lease Expiration Year LeaseExpirationYear	2018
CY2014Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2250000	shares
CY2013Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5750000	shares
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y10M24D
CY2013Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
CY2013Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	20058472	shares
CY2013Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21242979	shares
CY2013Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.14
CY2013Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1184507	shares
CY2013Q3	us-gaap	Revenue From Grants RevenueFromGrants	121000
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	200000
CY2013Q3	us-gaap	License And Services Revenue LicenseAndServicesRevenue	20111000
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	7158000
CY2013Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-554000
CY2013Q3	us-gaap	Revenues Revenues	20232000
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	169000
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	6604000
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11088000
CY2013Q3	us-gaap	Participating Securities Distributed And Undistributed Earnings Loss Basic ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic	6404000
CY2013Q3	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	6435000
CY2013Q3	us-gaap	Costs And Expenses CostsAndExpenses	13074000
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1986000
CY2013Q3	us-gaap	Share Based Compensation ShareBasedCompensation	137000
CY2013Q3	mgnx	Contingent Consideration Recorded As Incremental In Process Research And Development Expense ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense	0
CY2014Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2014Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27751437	shares
CY2014Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2014Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27751437	shares
CY2014Q3	us-gaap	Revenue From Grants RevenueFromGrants	99000
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-3928000
CY2014Q3	us-gaap	License And Services Revenue LicenseAndServicesRevenue	18283000
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3928000
CY2014Q3	us-gaap	Revenues Revenues	18382000
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3928000
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-3928000
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18632000
CY2014Q3	us-gaap	Costs And Expenses CostsAndExpenses	22310000
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3678000
CY2014Q3	us-gaap	Share Based Compensation ShareBasedCompensation	856000
CY2014Q3	mgnx	Contingent Consideration Recorded As Incremental In Process Research And Development Expense ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense	0

Files In Submission

Name	View Source	Status
0001193125-14-407501-index-headers.html	Edgar Link	pending
0001193125-14-407501-index.html	Edgar Link	pending
0001193125-14-407501.txt	Edgar Link	pending
0001193125-14-407501-xbrl.zip	Edgar Link	pending
d786329d10q.htm	Edgar Link	pending
d786329dex311.htm	Edgar Link	pending
d786329dex312.htm	Edgar Link	pending
d786329dex321.htm	Edgar Link	pending
d786329dex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
mgnx-20140930.xml	Edgar Link	completed
mgnx-20140930.xsd	Edgar Link	pending
mgnx-20140930_cal.xml	Edgar Link	unprocessable
mgnx-20140930_def.xml	Edgar Link	unprocessable
mgnx-20140930_lab.xml	Edgar Link	unprocessable
mgnx-20140930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MGNX
MACROGENICS INC Stock $mgnx

2014 Q4 Form 10-Q Financial Statement

#000119312514407501 Filed on November 12, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MGNX MACROGENICS INC Stock $mgnx

2014 Q4 Form 10-Q Financial Statement

#000119312514407501 Filed on November 12, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MGNX
MACROGENICS INC Stock $mgnx